MetaVia Inc. (NASDAQ:MTVA) Shares Shorted: Short Interest Down 36.0% in September

MetaVia Inc. (NASDAQ:MTVA) was the recipient of a significant decrease in short interest in September. As of September 30th, there was short interest totaling 117,409 shares, a decrease of 36.0% from the September 15th total of 183,472 shares. Approximately 2.3% of the company’s stock are sold short. Based on an average daily trading volume, of 57,790 shares, the short-interest ratio is currently 2.0 days.

Analysts Set New Price Targets

Several brokerages recently weighed in on MTVA. HC Wainwright reissued a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Wall Street Zen raised MetaVia to a “sell” rating in a research report on Saturday, June 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research report on Tuesday, July 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, MetaVia presently has a consensus rating of “Hold” and an average price target of $20.00.

MetaVia Stock Up 0.7%

MTVA opened at $1.37 on Friday. The firm has a 50 day moving average price of $1.58 and a 200-day moving average price of $1.66. The stock has a market capitalization of $7.07 million, a price-to-earnings ratio of -0.42 and a beta of 0.96. MetaVia has a twelve month low of $0.97 and a twelve month high of $14.85.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). As a group, analysts expect that MetaVia will post -2.79 earnings per share for the current year.

About MetaVia

MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s programs are designed to address conditions including excess weight, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease associated with metabolic dysfunction.

MetaVia’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed as a potential treatment for obesity and related metabolic complications.